Abrogation of cisplatin-induced nephrotoxicity by emodin in rats

Badreldin H. Ali, Suhail Al-Salam, Isehaq S. Al Husseini, Intisar Al-Lawati, Mostafa Waly, Javed Yasin, Mohamed Fahim, Abderrahim Nemmar

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Nephrotoxicity of the anticancer drug cisplatin (CP) involves the generation of reactive oxygen species in renal cortex, and emodin (a rhubarb anthraquinone) has strong antioxidant and anticancer actions. Therefore, we tested here the possible ameliorative effect of emodin on CP nephrotoxicity in rats. Emodin was given orally (10mg/kg/day for nine consecutive days), and on day 4, some of the treated rats were also injected intraperitoneally with either saline or CP (6mg/kg). Five days after CP treatment, rats were killed, and blood and urine samples, and kidneys were collected for the assessment of histopathological renal damage and apoptosis, and for biochemical estimation of creatinine and urea concentrations in plasma and urine, several cytosolic antioxidant enzyme activities in kidneys, and urinalyses. CP significantly increased the concentrations of urea and creatinine, and decreased creatinine clearance. It also significantly reduced cortical glutathione concentration and the activity of superoxide dismutase. CP treatment significantly increased urine volume and N-acetyl-β-D-glucosaminidase activity and significantly decreased osmolarity and protein concentrations. Emodin treatment markedly and significantly mitigated all these effects. Sections from saline- and emodin-treated rats showed apparently normal proximal tubules. However, kidneys of CP-treated rats had a moderate degree of necrosis. This was markedly lessened when CP was given simultaneously with emodin. The concentration of CP in the cortical tissues was not significantly altered by emodin treatment. The results suggested that emodin had ameliorated CP nephrotoxicity in rats. Pending further pharmacological and toxicological studies emodin may be considered a potentially useful nephroprotective agent.

Original languageEnglish
Pages (from-to)192-200
Number of pages9
JournalFundamental and Clinical Pharmacology
Volume27
Issue number2
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Emodin
Cisplatin
Kidney
Creatinine
Urine
Urea
Antioxidants
Rheum
Hexosaminidases
Anthraquinones
Urinalysis
Osmolar Concentration
Toxicology
Superoxide Dismutase
Glutathione
Reactive Oxygen Species
Necrosis

Keywords

  • Cisplatin
  • Emodin
  • Nephrotoxicity
  • Rats

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Abrogation of cisplatin-induced nephrotoxicity by emodin in rats. / Ali, Badreldin H.; Al-Salam, Suhail; Al Husseini, Isehaq S.; Al-Lawati, Intisar; Waly, Mostafa; Yasin, Javed; Fahim, Mohamed; Nemmar, Abderrahim.

In: Fundamental and Clinical Pharmacology, Vol. 27, No. 2, 04.2013, p. 192-200.

Research output: Contribution to journalArticle

Ali, BH, Al-Salam, S, Al Husseini, IS, Al-Lawati, I, Waly, M, Yasin, J, Fahim, M & Nemmar, A 2013, 'Abrogation of cisplatin-induced nephrotoxicity by emodin in rats', Fundamental and Clinical Pharmacology, vol. 27, no. 2, pp. 192-200. https://doi.org/10.1111/j.1472-8206.2011.01003.x
Ali, Badreldin H. ; Al-Salam, Suhail ; Al Husseini, Isehaq S. ; Al-Lawati, Intisar ; Waly, Mostafa ; Yasin, Javed ; Fahim, Mohamed ; Nemmar, Abderrahim. / Abrogation of cisplatin-induced nephrotoxicity by emodin in rats. In: Fundamental and Clinical Pharmacology. 2013 ; Vol. 27, No. 2. pp. 192-200.
@article{f7e7fc037b454eb1a7c58ecda681a4e3,
title = "Abrogation of cisplatin-induced nephrotoxicity by emodin in rats",
abstract = "Nephrotoxicity of the anticancer drug cisplatin (CP) involves the generation of reactive oxygen species in renal cortex, and emodin (a rhubarb anthraquinone) has strong antioxidant and anticancer actions. Therefore, we tested here the possible ameliorative effect of emodin on CP nephrotoxicity in rats. Emodin was given orally (10mg/kg/day for nine consecutive days), and on day 4, some of the treated rats were also injected intraperitoneally with either saline or CP (6mg/kg). Five days after CP treatment, rats were killed, and blood and urine samples, and kidneys were collected for the assessment of histopathological renal damage and apoptosis, and for biochemical estimation of creatinine and urea concentrations in plasma and urine, several cytosolic antioxidant enzyme activities in kidneys, and urinalyses. CP significantly increased the concentrations of urea and creatinine, and decreased creatinine clearance. It also significantly reduced cortical glutathione concentration and the activity of superoxide dismutase. CP treatment significantly increased urine volume and N-acetyl-β-D-glucosaminidase activity and significantly decreased osmolarity and protein concentrations. Emodin treatment markedly and significantly mitigated all these effects. Sections from saline- and emodin-treated rats showed apparently normal proximal tubules. However, kidneys of CP-treated rats had a moderate degree of necrosis. This was markedly lessened when CP was given simultaneously with emodin. The concentration of CP in the cortical tissues was not significantly altered by emodin treatment. The results suggested that emodin had ameliorated CP nephrotoxicity in rats. Pending further pharmacological and toxicological studies emodin may be considered a potentially useful nephroprotective agent.",
keywords = "Cisplatin, Emodin, Nephrotoxicity, Rats",
author = "Ali, {Badreldin H.} and Suhail Al-Salam and {Al Husseini}, {Isehaq S.} and Intisar Al-Lawati and Mostafa Waly and Javed Yasin and Mohamed Fahim and Abderrahim Nemmar",
year = "2013",
month = "4",
doi = "10.1111/j.1472-8206.2011.01003.x",
language = "English",
volume = "27",
pages = "192--200",
journal = "Fundamental and Clinical Pharmacology",
issn = "0767-3981",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Abrogation of cisplatin-induced nephrotoxicity by emodin in rats

AU - Ali, Badreldin H.

AU - Al-Salam, Suhail

AU - Al Husseini, Isehaq S.

AU - Al-Lawati, Intisar

AU - Waly, Mostafa

AU - Yasin, Javed

AU - Fahim, Mohamed

AU - Nemmar, Abderrahim

PY - 2013/4

Y1 - 2013/4

N2 - Nephrotoxicity of the anticancer drug cisplatin (CP) involves the generation of reactive oxygen species in renal cortex, and emodin (a rhubarb anthraquinone) has strong antioxidant and anticancer actions. Therefore, we tested here the possible ameliorative effect of emodin on CP nephrotoxicity in rats. Emodin was given orally (10mg/kg/day for nine consecutive days), and on day 4, some of the treated rats were also injected intraperitoneally with either saline or CP (6mg/kg). Five days after CP treatment, rats were killed, and blood and urine samples, and kidneys were collected for the assessment of histopathological renal damage and apoptosis, and for biochemical estimation of creatinine and urea concentrations in plasma and urine, several cytosolic antioxidant enzyme activities in kidneys, and urinalyses. CP significantly increased the concentrations of urea and creatinine, and decreased creatinine clearance. It also significantly reduced cortical glutathione concentration and the activity of superoxide dismutase. CP treatment significantly increased urine volume and N-acetyl-β-D-glucosaminidase activity and significantly decreased osmolarity and protein concentrations. Emodin treatment markedly and significantly mitigated all these effects. Sections from saline- and emodin-treated rats showed apparently normal proximal tubules. However, kidneys of CP-treated rats had a moderate degree of necrosis. This was markedly lessened when CP was given simultaneously with emodin. The concentration of CP in the cortical tissues was not significantly altered by emodin treatment. The results suggested that emodin had ameliorated CP nephrotoxicity in rats. Pending further pharmacological and toxicological studies emodin may be considered a potentially useful nephroprotective agent.

AB - Nephrotoxicity of the anticancer drug cisplatin (CP) involves the generation of reactive oxygen species in renal cortex, and emodin (a rhubarb anthraquinone) has strong antioxidant and anticancer actions. Therefore, we tested here the possible ameliorative effect of emodin on CP nephrotoxicity in rats. Emodin was given orally (10mg/kg/day for nine consecutive days), and on day 4, some of the treated rats were also injected intraperitoneally with either saline or CP (6mg/kg). Five days after CP treatment, rats were killed, and blood and urine samples, and kidneys were collected for the assessment of histopathological renal damage and apoptosis, and for biochemical estimation of creatinine and urea concentrations in plasma and urine, several cytosolic antioxidant enzyme activities in kidneys, and urinalyses. CP significantly increased the concentrations of urea and creatinine, and decreased creatinine clearance. It also significantly reduced cortical glutathione concentration and the activity of superoxide dismutase. CP treatment significantly increased urine volume and N-acetyl-β-D-glucosaminidase activity and significantly decreased osmolarity and protein concentrations. Emodin treatment markedly and significantly mitigated all these effects. Sections from saline- and emodin-treated rats showed apparently normal proximal tubules. However, kidneys of CP-treated rats had a moderate degree of necrosis. This was markedly lessened when CP was given simultaneously with emodin. The concentration of CP in the cortical tissues was not significantly altered by emodin treatment. The results suggested that emodin had ameliorated CP nephrotoxicity in rats. Pending further pharmacological and toxicological studies emodin may be considered a potentially useful nephroprotective agent.

KW - Cisplatin

KW - Emodin

KW - Nephrotoxicity

KW - Rats

UR - http://www.scopus.com/inward/record.url?scp=84874384385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874384385&partnerID=8YFLogxK

U2 - 10.1111/j.1472-8206.2011.01003.x

DO - 10.1111/j.1472-8206.2011.01003.x

M3 - Article

VL - 27

SP - 192

EP - 200

JO - Fundamental and Clinical Pharmacology

JF - Fundamental and Clinical Pharmacology

SN - 0767-3981

IS - 2

ER -